References
- 1. Cheemerla S., Balakrishnan M. (2021) Global epidemiology of chronic liver disease. Clin. Liver Dis. (Hoboken), 17(5): 365–370. DOI: 10.1002/cld.1061.
- 2. Björkström K., Franzén S., Eliasson B. et al. (2016) Risk factors for severe liver disease in patients with type 2 diabetes. Clin. Gastroenterol. Hepatol., 17(13): 2769–2775.
- 3. Pimpin L., Cortez-Pinto H., Negro F. et al. (2018) Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J. Hepatol., 69(3): 718–735.
- 4. Sotoudehmanesh R., Sotoudeh M., Ali-Asgari A. et al. (2006) Silent liver diseases in autopsies from forensic medicine of Tehran. Arch. Iran Med., 9(4): 324–328.
- 5. Raszeja-Wyszomirska J., Lawniczak M., Marlicz W. et al. (2008) Non-alcoholic fatty liver disease — new view. Pol. Merkur Lekarski, 24(144): 568–571.
- 6. Lala V., Zubair M., Minter D.A. (2022) Liver Function Tests.
- 7. Шерлок Ш., Дули Д. (2002) Заболевания печени и желчных путей. Практическое руководство. (пер. с англ.). ГЭОТАР-Медиа, Москва, 864 с.
- 8. Вялов С.С. (2012) Алгоритмы диагностики. МЕДпресс-информ, Москва, 127 c.
- 9. Chalasani N., Younossi Z., Lavine J.E. et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55(6): 2005–2023. doi: 10.1002/hep.25762.
- 10. Підгірний Я.М. (2018) Гостра печінкова дисфункція і вагітність. Мед. неотл. сост., 3: 7–13.
- 11. Sharma A., Nagalli S. (2023) Chronic Liver Disease.
- 12. European Association for the Study of the Liver (2021) EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol., 75(3): 659–689. doi: 10.1016/j.jhep.2021.05.025.
- 13. Налапко К.К., Гетьманенко О.А., Купершмидт В.Р. та ін. (2012) Синдром эндогенной интоксикации и его гепатотропная коррекция в клинической практике. Укр. журн. екстрем. мед. імені Г.О. Можаєва, 13(2): 28–33.
- 14. Balcar L., Krawanja J., Scheiner B. et al. (2023) Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease. JHEP Rep., 5(4): 100682.
- 15. Kjærgaard K., Mikkelsen A.C.D., Wernberg C.W. et al. (2021) Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. J. Clin. Med., 10(4): 673. DOI: 10.3390/jcm10040673.
- 16. Kimelberg H.K. (2005) Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy. Glia, 50: 389–397.
- 17. De Chiara F., Habiesion A., Davies N. et al. (2017) Early increase in ammonia is a feature of Non-Alcogolic Fatty Liver Disease and the ammonia lovering drug, Ornithine Phenylacetate (OP-OCR002) prevents progression of fibrosis in a rodent model. J. Clin. Exp. Hepatol., 7(1): S73–S74. DOI: 10.1016/j.jceh.2017.01.099.
- 18. clinicaltrials.gov/ct2/show/NCT01847651.
- 19. Zafiris O., Kircheis G., Rood H.A. et al. (2004). Neural mechanism underlying impaired visual judgement in the dysmetabolic brain: an fMRI study. Neuroimage, 22(2): 541–552.
- 20. Butterworth R.F. (2019) l-Ornithine l-aspartate: multimodal therapeutic agent for hyperammonemia and hepatic encephalopathy in cirrhosis. J. Pharmacol. Pharm. Res., 2(3): 1–7.
- 21. De Chiara F., Thomsen K.L., Habtesion A. et al. (2020) Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease. Hepatology, 71(3): 874–892.
- 22. Panasiuk A. (2014) Encefalopatia wątrobowa. In: Forum Medycyny Rodzinnej, 8(2): 64–75.
- 23. Gutiérrez-de-Juan V., López de Davalillo S., Fernández-Ramos D. et al. (2017) A morphological method for ammonia detection in liver. PLoS One, 12: e0173914.
- 24. Stauch S., Kircheis G., Adler G. et al. (1998) Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J. Hepatol., 28(5): 856–864.
- 25. Kircheis G., Wettstein M., vom Dahl S., Häussinger D. (2002) Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab. Brain Dis., 17(4): 453–462.
- 26. Bai M., He C., Yin Z. et al. (2014) Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment. Pharmacol. Ther., 40(1): 63–71. DOI: 10.1111/apt.12795.
- 27. Geng X.-X., Huang R.-G., Lin J.-M. et al. (2016) Transient Elastography in Clinical Detection of Liver Cirrhosis: A Sys-tematic Review and Meta-analysis. Saudi J. Gastroenterol., 22(4): 294–303. doi: 10.4103/1319-3767.187603.
- 28. Sporea I., Popescu A., Sirli R. (2008) Why, who and how should perform liver biopsy in chronic liver diseases. World J. Gastroenterol., 14(21): 3396–3402.